Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.31 |
| ▸ | KMO | O15229 | 2/20 | 0.31 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.31 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17358311 | 0.78 | HTR3E (0.33) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16478274 | 0.77 | HTR3E (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16471319 | 0.74 | KMT2A (0.41) | KMT2A | |
| SCHEMBL8248239 | 0.73 | HTR3E (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL11287987 | 0.72 | HTR3E (0.40) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16471303 | 0.70 | HTR3E (0.40) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL13648126 | 0.70 | HTR3E (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16471305 | 0.70 | TRPV4 (0.44) | KMT2A | |
| SCHEMBL11655245 | 0.69 | KMT2A (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL856525 | 0.69 | MAPK1 (0.61) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | HTR3E 3876/4885HTR3B 3302/4885HTR3A 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.